Triple Combination CF Medication for Less Common Genetic Mutations

Trial Objective

Triple Combination CF Medication for Less Common Genetic MutationsThis trial evaluates triple combination therapy for people with cystic fibrosis that have the genetic mutations that are currently eligible for Symdeko or Kalydeco. This therapy is made up of the drugs ivacaftor, tezacaftor and elexacaftor.  Researchers are trying to determine if this therapy is better than Symdeko and Kalydeco, at improving lung function and digestion for people with CF with specific CF mutations.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

People with CF who are eligible to be on Symdeko or Kalydeco.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

6 visits approximately every 2 weeks during the 12 week trial.

Appointments can be up to 4 hours.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Connor Balkissoon

Connor Balkissoon
303.270.2768

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals, Inc.

Principal Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*